Organization
Prisma Health Cancer Institute
7 abstracts
Abstract
Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors.Org: The University of Texas MD Anderson Cancer Center, Hospital Universitario 12 de Octubre, NCT Heidelberg, Charité Universitätsmedizin Berlin, Prisma Health Cancer Institute,
Abstract
MT-6402, an engineered toxin body (ETB) targeting PD-L1: Interim efficacy and safety data.Org: Mary Crowley Cancer Research Center, Washington University in Saint Louis, Brown Cancer Center, Sanford Cancer Center, Prisma Health Cancer Institute,
Abstract
Identification and management of clonal hematopoiesis of indeterminate potential (CHIP) in cancer survivors: The Cleveland Clinic experience.Org: Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Sylvester Comprehensive Cancer Center, Miami, FL,
Abstract
A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non–small-cell lung cancer.Org: Lung Cancer Research, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Sarah Cannon Research Institute at HealthONE, Next Oncology Virginia and Virginia Cancer Specialists,
Abstract
Intravenous (IV) infusion of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, as monotherapy in advanced solid tumors: Preliminary results from an ongoing phase 1/2a study.Org: Banner MD Anderson Cancer Center, Mary Crowley Cancer Research Center, Virginia Health Specialists, Fairfax, VA, Prisma Health Cancer Institute, ImmVira Co., Limited,
Abstract
Nationwide phase II randomized controlled trial of low-dose ibuprofen vs placebo for cancer-related cognitive impairment (CRCI).Org: University of Rochester Medical Center, Wilmot Cancer Institute, Rochester, NY, University of Rochester Medical School, AdventHealth Orlando,
Abstract
Identifying sources and mechanisms for missed opportunities in discussing cognition and capacity among older adults with advanced cancer, their caregivers, and physicians.Org: URMC, Rochester, NY, University of Rochester Medical School, University of Rochester Medical Center, James P. Wilmot Cancer Insititute,